About ClearSight
A dedicated resource for the inherited retinal disease community — patients, families, researchers, and clinicians.
Our Mission
ClearSight IRD Research Hub was created to bridge the information gap between cutting-edge retinal research and the patients and families who need it most. Inherited retinal diseases (IRDs) are a diverse group of rare genetic conditions affecting approximately 1 in 2,000 people worldwide — yet many patients and families struggle to find accurate, up-to-date information about their specific condition.
We monitor scientific literature, clinical trial registries, FDA announcements, and medical news to deliver timely, accurate, and accessible information. Our AI-powered research engine continuously tracks developments in the field, ensuring our blog reflects the latest advances in gene therapy, clinical trials, and emerging treatments.
Our Pillars
Scientific Accuracy
Every article is grounded in peer-reviewed research and reviewed for medical accuracy before publication.
Accessible Language
We translate complex genetics and clinical science into clear, understandable language for patients and families.
Patient Focus
Our content is designed to empower patients and caregivers with actionable information about their condition.
Genetic Depth
We cover the genetics of each IRD in detail, including inheritance patterns, causative genes, and genetic testing.
Community
We connect readers to patient organizations, clinical trials, and research communities worldwide.
Timely Updates
Our AI-powered research engine monitors the latest publications, trials, and news to keep content current.
Medical Disclaimer
ClearSight is an informational resource only. Content on this website does not constitute medical advice, diagnosis, or treatment recommendations. Always consult a qualified ophthalmologist, retinal specialist, or genetic counselor for medical decisions. Clinical trial information is provided for awareness purposes and does not constitute an endorsement or recommendation to participate.